Evidence map›Paper›PMID 38288222›Full record

ReviewCureus2023

Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review.

Collyn O'Quin, Kathryn L White, John R Campbell, Sarah H Myers, Shilpadevi Patil, Debbie Chandler, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Effect of time between archwire changes on intended dentoalveolar expansion in orthodontic patients treated with fixed appliances : A prospective controlled clinical trial.Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie · 2026
    Trial
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Collyn O'QuinSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Kathryn L WhiteSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
John R CampbellSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Sarah H MyersSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Shilpadevi PatilAnesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Debbie ChandlerSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Shahab AhmadzadehAnesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.
Sahar ShekoohiAnesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Alan D KayeAnesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Fondazione Roma · ITLouisiana State University Health Sciences Center Shreveport · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign Prostatic Hyperplasia (BPH) is a prevalent condition that affects aging men, leading to the development of lower urinary tract symptoms (LUTS) and potentially severe complications such as complete obstruction. The management of BPH typically involves the use of medications from different classes, including alpha-1 antagonists, 5-alpha reductase inhibitors, and anticholinergics. Combination therapy utilizing drugs from different classes can also effectively manage the BPH-LUTS complex. Recent research has revealed that phosphodiesterase 5 (PDE5) inhibitors, including Tadalafil and Sildenafil, are highly effective in treating LUTS associated with BPH. Tadalafil as a monotherapy has recently been shown to significantly improve LUTS in BPH patients. Additionally, the use of herbal remedies as a treatment option for BPH has also been widely debated. Previous research suggests that saw palmetto can reduce BPH symptoms through several proposed mechanisms, but recent trials have found inconsistencies in its efficacy. In this literature review, we conducted an extensive PubMed database search to provide current and comprehensive insights into BPH treatment options. This review comprehensively evaluates available treatments for managing BPH, highlighting the effectiveness of different classes of medications and combination therapies in managing associated symptoms. The present investigation also discusses recent research on the efficacy of PDE5 inhibitors in treating LUTS associated with BPH and the uncertain efficacy of herbal remedies. The insights provided by this study can guide healthcare professionals in making informed decisions about managing BPH, ultimately improving patient outcomes.

Indexed as

benign prostatic hyperplasiafinasteridelower urinary tract symptomspyegeum africanumsaw palmettosildenafiltadalafilterazosin

Identifiers

PMID38288222
PMCPMC10823302
OpenAlexW4390447988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.